ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1664347
This article is part of the Research TopicNeural influences on tumor immunity: Exploring neuroimmunology in cancerView all 12 articles
Deciphering the Lactylation Landscape in Glioma: A Novel Gene Signature Predicts Patient Survival and Immunotherapy Sensitivity
Provisionally accepted- 1Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
- 2The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, China
- 3The Second People's Hospital of Lianyungang, Lianyungang, China
- 4Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Glioma, the most prevalent primary brain tumor, takes advantage of lactylation, a metabolic modification linked to tumor behavior and clinical outcomes. Despite its significance, the role of lactylation in the pathogenesis and prognosis of glioma remains underexplored. This study established a lactylation-derived molecular signature to predict survival and response to immunotherapy in glioma. Methods: Leveraging the TCGA glioma cohort, we established a lactylation-related gene (LRG) signature via LASSO and Cox regression analyses, and its prognostic value was validated in independent cohorts. We comprehensively characterized the associations between the LRGs signature and clinicopathological features, tumor immunity (immune infiltration and response to immunotherapy), genomic instability (mutational burden and heterogeneity), tumor stemness, and therapeutic vulnerability. In vitro validation of the oncogenicity of HSPE1 was conducted using the CCK-8, colony formation, transwell, and apoptosis assays in U87 and U251 glioma cells. Results: A four-gene lactylation signature (KIF2C, CALD1, HSPE1, and IFI16) was identified. Elevated LRGs score were correlated with advanced tumor grade, poor prognosis, and reduced response to immunotherapy. Patients in the LRGs-high group exhibited adverse clinicopathological features, including advanced age, higher WHO grade, IDH wild-type status, and 1p/19q non-codeletion. The nomogram model based on the LRGs score exhibited robust prognostic accuracy (C-index = 0.860). LRGs-related genes were enriched in immune regulatory pathways, such as cytokine signaling and interferon-γ response pathways. The LRGs-high group displayed increased infiltration of immunosuppressive cells, such as M2 macrophages, MDSCs, and CAFs, and distinct genomic instability profiles. Crucially, HSPE1 knockdown significantly suppressed the proliferation and invasion of glioma cell lines. Conclusions: We defined a novel LRGs signature integrating metabolic and immune dysregulation in glioma. This signature served as an independent predictor of prognosis and immunotherapy. Furthermore, we identified HSPE1 as a critical driver of glioma progression.
Keywords: Glioma, lactylation, HSPE1, prognosis, Immunotherapy
Received: 11 Jul 2025; Accepted: 01 Sep 2025.
Copyright: © 2025 Tang, Liu, Yang, Zhang, Zhang, Wang, Jiang, Gao, Liu and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiaolong Tang, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
Yongshuo Liu, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Yanbin Dong, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.